{{Drugbox
| verifiedrevid = 448134770
| IUPAC_name = 3,3',3<nowiki>''</nowiki>,3<nowiki>'''</nowiki>-(2,3-dihydroporphyrin-5,10,15,20-tetrayl)tetraphenol
| image = Temoporfin.png

<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|temoporfin}}
| licence_EU = Foscan
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status = Rx-only
| routes_of_administration =  

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 122341-38-2
| ATC_prefix = L01
| ATC_suffix = XD05
| ATC_supplemental =  
| PubChem = 60751
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChEMBL = 383675
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = FU21S769PF
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D06066
| ChemSpiderID      = 54754

<!--Chemical data-->
| chemical_formula =  
| C=44 | H=32 | N=4 | O=4 
| molecular_weight = 680.74 g/mol
| smiles            = c1cc(cc(c1)O)c2/c3ccc([nH]3)/c(c/4\nc(/c(c\5/cc/c(/[nH]5)c(/c6n\c2\CC6)\c7cccc(c7)O)/c8cccc(c8)O)C=C4)/c9cccc(c9)O
| StdInChI          = 1S/C44H32N4O4/c49-29-9-1-5-25(21-29)41-33-13-15-35(45-33)42(26-6-2-10-30(50)22-26)37-17-19-39(47-37)44(28-8-4-12-32(52)24-28)40-20-18-38(48-40)43(36-16-14-34(41)46-36)27-7-3-11-31(51)23-27/h1-17,19,21-24,46-47,49-52H,18,20H2/b41-33-,41-34-,42-35-,42-37-,43-36-,43-38-,44-39-,44-40-
| StdInChIKey       = LYPFDBRUNKHDGX-LWQDQPMZSA-N
}}

'''Temoporfin''' ([[International Nonproprietary Name|INN]]) is a [[photosensitizer]] (based on [[chlorin]]) used in [[photodynamic therapy]] for the treatment of [[squamous cell carcinoma]] of the [[head and neck cancer|head and neck]]<ref name="pmid17516041">{{cite journal |vauthors=Lorenz KJ, Maier H |title=[Squamous cell carcinoma of the head and neck. Photodynamic therapy with Foscan] |language=German |journal=HNO |volume=56 |issue=4 |pages=402â€“9 |date=April 2008 |pmid=17516041 |doi=10.1007/s00106-007-1573-1 |url=}}</ref>
.<ref name=OGB2009>{{cite news |url=http://findarticles.com/p/articles/mi_qa3931/is_200909/ai_n42040200/pg_7/ |title=Porphyrin and Nonporphyrin Photosensitizers in Oncology: Preclinical and Clinical Advances in Photodynamic Therapy.  Photochemistry and Photobiology, Sep/Oct 2009 |author=O'Connor, Aisling E |author2=Gallagher, William M |author3=Byrne, Annette T | work=Photochemistry and Photobiology |year=2009}}</ref> 
It is marketed in the [[European Union]] under the brand name '''Foscan'''.  The U.S. [[Food and Drug Administration]] (FDA) declined to approve Foscan in 2000.  The EU approved its use in June 2001.<ref>http://www.highbeam.com/doc/1P2-18794532.html Foscan approval saves Scotia's skin.</ref>

Good results were obtained in 21 of 35 patients treated in Germany.<ref>http://www.springerlink.com/content/g74w224824v8l013/</ref>

It is photoactivated at 652&nbsp;nm<ref>{{cite news| url=http://findarticles.com/p/articles/mi_qa3931/is_200909/ai_n42040200/pg_7/ | work=Photochemistry and Photobiology | title=Porphyrin and Nonporphyrin Photosensitizers in Oncology: Preclinical and Clinical Advances in Photodynamic Therapy | year=2009}}</ref> i.e. by red light.

Patients can remain photosensitive for several weeks after treatment.<ref name=OGB2009/>

==Further reading==
*[http://www.nature.com/bjc/journal/v96/n6/full/6603631a.html Relationship between subcellular localisation of Foscan and caspase activation in photosensitised MCF-7 cells. Marchal et al. 2007]

==References==
{{reflist|30em}}

{{Chemotherapeutic agents}}

[[Category:Photosensitizing agents]]
[[Category:Tetrapyrroles]]


{{antineoplastic-drug-stub}}